Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ blood
COVID-19 Testing
Coronavirus Nucleocapsid Proteins
/ immunology
Female
Humans
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Longitudinal Studies
Male
Pharynx
/ virology
Phosphoproteins
/ immunology
RNA, Viral
/ genetics
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ immunology
COVID-19
SARS-CoV-2 N-protein
SARS-CoV-2 RT-qPCR
SARS-CoV-2 S1-RDB protein
SARS-CoV-2 neutralizing activity
anti-SARS-CoV-2 antibodies
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 11 2020
27 11 2020
Historique:
received:
09
11
2020
revised:
23
11
2020
accepted:
24
11
2020
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
22
12
2020
Statut:
epublish
Résumé
The relationship between the nasopharyngeal virus load, IgA and IgG antibodies to both the S1-RBD-protein and the N-protein, as well as the neutralizing activity (NAbs) against SARS-CoV-2 in the blood of moderately afflicted COVID-19 patients, needs further longitudinal investigation. Several new serological methods to examine these parameters were developed, validated and applied in three patients of a family which underwent an ambulatory course of COVID-19 for six months. The virus load had almost completely disappeared after about four weeks. Serum IgA levels to the S1-RBD-protein and, to a lesser extent, to the N-protein, peaked about three weeks after clinical disease onset but declined soon thereafter. IgG levels rose continuously, reaching a plateau at approximately six weeks, and stayed elevated over the observation period. Virus-neutralizing activity reached a peak about 4 weeks after disease onset but dropped slowly. The longitudinal associations of virus neutralization and the serological immune response suggest immunity in patients even after a mild clinical course of COVID-19.
Identifiants
pubmed: 33260809
pii: v12121357
doi: 10.3390/v12121357
pmc: PMC7761220
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulin A
0
Immunoglobulin G
0
Phosphoproteins
0
RNA, Viral
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : xxxxxx
Pays : International
Organisme : University Hospital Tuebingen
ID : xxxxxx
Pays : International
Organisme : Baden-Württemberg Foundation
ID : xxxxxxx
Pays : International
Organisme : Deutsche Herzstiftung
ID : 0
Pays : International
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Infect. 2020 Jul;81(1):179-182
pubmed: 32283139
Sci Transl Med. 2020 Dec 7;:
pubmed: 33288662
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Biochem Biophys Res Commun. 2020 Jun 30;527(3):618-623
pubmed: 32416961
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Emerg Infect Dis. 2020 Aug;26(8):1834-1838
pubmed: 32383638
Int J Surg. 2020 Jun;78:123-125
pubmed: 32360932
J Infect Dis. 1979 Oct;140(4):527-33
pubmed: 117061
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508